PDCD1 and gastric cancer: To our knowledge, this study is the first to assess the cost-effectiveness of cadonilimab, a second-generation PD-1 inhibitor, combined with chemotherapy as a first-line therapy for GC/GEJC from both the U.S. and Chinese payer perspectives.